Video of the quarter
PHERAstar FSX supports the diverse and changing needs of CROs - Q1 2019

Sygnature Discovery is a Contract Research Organisation specialized in supporting clients´ projects by providing integrated drug discovery resources. This is mainly achieved by assessing the pharmacology and functionality of novel compounds or targets.

Sygnature Discovery routinely utilises a plethora of biochemical assays including all detection modes which are measured on BMG LABTECH’s Microplate Reader PHERAstar FSX. The Reader was chosen for its sensitivity, reliability and flexibility.

The flexibility of the reader helps to match the diverse and changing needs CROs have to face when tackling different drug discovery projects. The sensitivity and reliability enabled the design of very challenging bespoke assays that could to be performed on other assays.